Nivonirina Robinot

Nivonirina Robinot

Auto-generated profile, based on publicly available information

Nivonirina Robinot

International Agency for Research on Cancer, 69372 Lyon, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
TGTanja Gumpenberger
Tanja Gumpenberger
SBStefanie Brezina
Stefanie Brezina
PKPekka Keski-Rahkonen
Pekka Keski-Rahkonen
ABAndreas Baierl
Andreas Baierl
NRNivonirina Robinot
Nivonirina Robinot
AGAndrea Gsur
Andrea Gsur
Sporadic colorectal cancer is characterized by a multistep progression from normal epithelium to precancerous low-risk and high-risk adenomas to invasive cancer. Yet, the underlying molecular mechanisms of colorectal carcinogenesis are not completely understood. Within the “Metabolomic profiles throughout the continuum of colorectal cancer” (MetaboCCC) consortium we analyzed data generated by untargeted, mass spectrometry-based metabolomics using plasma from 88 colorectal cancer patients, 200 patients with high-risk adenomas and 200 patients with low-risk adenomas recruited within the “Colorectal Cancer Study of Austria” (CORSA). Univariate logistic regression models comparing colorectal cancer to adenomas resulted in 442 statistically significant molecular features. Metabolites discriminating colorectal cancer patients from those with adenomas in our dataset included acylcarnitines, caffeine, amino acids, glycerophospholipids, fatty acids, bilirubin, bile acids and bacterial metabolites of tryptophan. The data obtained discovers metabolite profiles reflecting metabolic differences between colorectal cancer and colorectal adenomas and delineates a potentially underlying biological interpretation.